Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL875563 | 0.79 | ACHE (0.44) | ACHE | |
| SCHEMBL23201919 | 0.70 | JAK2 (0.39) | ACHE | |
| SCHEMBL18555455 | 0.69 | — | — | |
| SCHEMBL34471153 | 0.69 | — | — | |
| SCHEMBL13948950 | 0.68 | ACHE (0.35) | ACHE | |
| SCHEMBL12755533 | 0.67 | — | — | |
| SCHEMBL17102326 | 0.67 | — | — | |
| SCHEMBL152391 | 0.67 | — | — | |
| SCHEMBL3262269 | 0.67 | — | — | |
| SCHEMBL30854866 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264954-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| WO-2024249642-A1 | EGFR INHIBITORS | ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024149378-A1 | QUINOLINONE COMPOUND AND NAPHTHYRIDINONE COMPOUND AND USE THEREOF | 上海超阳药业有限公司 | 2024-07-18 | — | — | WO | disclosed |
| CN-117940437-A | DNA-PK selective inhibitor and preparation method and application thereof | 首药控股(北京)股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117865952-A | RET selective inhibitor and preparation method and application thereof | 首药控股(北京)股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-112574191-B | Isoxazole heterocyclic compound and application thereof | 南京圣和药业股份有限公司 | 2024-01-23 | — | — | CN | disclosed |
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | WELLS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| CN-114072404-B | RET selective inhibitor and preparation method and application thereof | 首药控股(北京)股份有限公司 | 2023-09-15 | — | — | CN | disclosed |
| WO-2023169453-A1 | HETEROAROMATIC RING-CONTAINING ALKYNYL COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2023-09-14 | — | — | WO | disclosed |
| US-20230119740-A1 | THERAPEUTIC COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-2902392-A1 | Fused heteroaromatic pyrrolidinones as syk inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2015-08-05 | — | — | EP | disclosed |
| EP-2516434-B1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2015-05-27 | — | — | EP | disclosed |
| CN-102753548-B | Fused heteroaromatic pyrrolidones as SYK inhibitors | TAKAEDA CHEMICAL IND LTD | 2015-03-11 | — | — | CN | disclosed |
| US-20130245031-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2013-09-19 | — | — | US | disclosed |
| US-8440689-B2 | Fused heteroaromatic pyrrolidinones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-14 | — | — | US | disclosed |
| US-20130116260-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-09 | — | — | US | disclosed |
| EP-2516434-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2012-10-31 | — | — | EP | disclosed |
| CN-102753548-A | Fused heteroaromatic pyrrolidones as SYK inhibitors | TAKAEDA CHEMICAL IND LTD | 2012-10-24 | — | — | CN | disclosed |
| WO-2011079051-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152273-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119740-A1 | THERAPEUTIC COMPOUNDS AND METHODS | PCK1, SLC5A1, PFKFB1 | ACHE 3159/4885 |
| US-20130116260-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | SYK, BTK, LYN | ACHE 3740/4885 |
| US-20130245031-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | ACHE 3330/4885 |
| US-20110152273-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | ACHE 3330/4885 |
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | ACHE 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.